- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06130449
Testosterone and Neural Function
The Role of Androgens in Neurophysiological and Autonomic Function in Male Veterans With Spinal Cord Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Spinal cord injury (SCI) disrupts sensorimotor function and corticospinal excitability, resulting in muscle weakness and autonomic nervous system (ANS) dysfunction that detracts from cardiovascular (CV) health. These deficits may be exacerbated by low testosterone (T), which develops in most men during the acute/subacute phases of SCI and persists in 45-60% of men thereafter. Low T (hypogonadism) is associated with multiple health impairments, including reduced lean tissue mass and increased fat mass, systemic inflammation, and risk for CV and neurodegenerative diseases. Moreover, low T is associated with CV ANS dysfunction and impaired cardiovagal (parasympathetic) tone following SCI. In men with low T after SCI, restoring T concentrations to the normal (eugonadal) range with T replacement therapy (TRT) improves energy expenditure, body composition, CV function, and markers of cardiometabolic health. Evidence from animal models also demonstrates that T is neuroprotective, upregulates neurotrophic factors, and promotes neuroplasticity and myelin regeneration. However, the neural effects of intranasal TRT are unknown.
T is the most abundant bioactive androgen within the circulation. It exerts direct biological actions by binding androgen receptors (ARs), affecting transcription, as well as non-genomic mechanisms in the brain, spinal cord, heart, and numerous other tissues throughout the body. The majority of circulating T is bound to sex-hormone binding globulin (SHBG) and albumin, with only 1-4% circulating unbound (free T). Free T and albumin-bound T are collectively termed bioavailable T, as SHBG-bound T cannot readily dissociate to engage cellular receptors. In this regard, a high prevalence of men with SCI not only exhibit low total T, but also exhibit a marked reduction in bioavailable T because there is a >10-fold increase in SHBG after SCI, resulting in lower proportions of free and albumin-bound T.
The primary goal of this proposal is to perform a small pilot/feasibility study to assess neurophysiological and cardiovagal responses to a single dose of intranasal TRT in a cohort of these men who exhibit low total T (<264 ng/dL) and hypogonadal symptoms.
Primary Aim: To investigate the acute effects of a single dose of intranasal TRT (11 mg) compared with placebo on CNS excitability and cardiovagal reflex function 30 minutes after administration in 10 male Veterans with chronic SCI who have low baseline total T concentrations. CNS excitability will be assessed using hand muscle electromyography (EMG) output determined by recruitment curves evoked by non-invasive single-pulse transcranial magnetic stimulation (TMS) and cervical transcutaneous spinal cord stimulation (TSCS). A cold face challenge while measuring beat-to-beat heart rate signals will be used to examine CV ANS reflex function. Because this Aim is a pilot/feasibility study, formal hypothesis testing would be premature. However, based on the literature, the investigators expect that elevating circulating concentrations of T into the high normal physiologic range via intranasal TRT will result in improved neural and cardiovagal function for 6-8 hours after the dose.
The results of this pilot study will inform feasibility and identify modifications needed to design a larger eventual trial to evaluate the efficacy and safety of intranasal TRT. Ours will be the first clinical study to collect pilot/feasibility data on an intranasal TRT formulation that has the potential to improve neural function after SCI. This is significant because our results are expected to provide evidence demonstrating the feasibility of a novel intranasal therapeutic strategy in Veterans with SCI.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Jacob A Goldsmith, PhD
- Phone Number: (718) 584-9000
- Email: Jacob.Goldsmith@va.gov
Study Contact Backup
- Name: Noam Y Harel, MD PhD
- Phone Number: 1742 (718) 584-9000
- Email: Noam.Harel@va.gov
Study Locations
-
-
New York
-
Bronx, New York, United States, 10468-3904
- Recruiting
- James J. Peters VA Medical Center, Bronx, NY
-
Contact:
- Finn (Fiona) Fox, BS
- Phone Number: 3128 718-584-9000
- Email: fiona.fox2@va.gov
-
Contact:
- Astrea Villarroel-Sanchez, MPH
- Phone Number: 3107 (718) 584-9000
- Email: astrea.villarroel-sanchez@va.gov
-
Principal Investigator:
- Jacob A Goldsmith, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-80 years
- Time since injury (TSI) more than 12 months
- Traumatic or non-traumatic SCI
- American Spinal Injury Association (ASIA) Injury classification Scale (AIS) A, B, C, or D
- Stable prescription medication regimen for at least 30 days
- Not currently receiving pharmacological treatment for hypogonadism
- Must be able to commit to study requirements of 3 visits within a 30-day period
- Provide informed consent
Exclusion Criteria:
- Extensive history of seizures
- Ventilator dependence or patent tracheostomy site
- History of neurologic disorder other than SCI
- History of moderate or severe head trauma
- Currently receiving treatment for hypogonadism
- History of allergy, hypersensitivity, or other significant adverse reaction to testosterone replacement therapy
- Significant cardiovascular disease or cardiac conduction disease
- Active psychological disorder
- Moderate or severe brain injury, stroke, tumor, multiple sclerosis, or abscess
- Recent history (within 3 months) of substance abuse
- Pressures sores stage 3 or greater
- Active infection
- Frequent severe migraines
- Recent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic pressure greater than 10 mm Hg, without rise in heart rate, accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, and blurry vision (this will be closely monitored during all screening and testing procedures)
- History of implanted devices with electromagnetic properties: brain/spine/nerve stimulators, aneurysm clips, ferromagnetic metallic implants in the head (except for inside mouth); cochlear implants; cardiac pacemaker/defibrillator; intracardiac lines; currently increased intracranial pressure; or other contraindications to brain or spine stimulation
- Use of medications that significantly lower seizure threshold, such as amphetamines, neuroleptics, dalfampridine, and bupropion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participant-blinded (Ayr Saline Gel)
|
A single dose of Ayr (one spray per nostril) will be administered to each participant.
Other Names:
|
Active Comparator: Intranasal TRT
Participant-blinded (11 mg of Natesto)
|
A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electromyographic responses
Time Frame: up to one day
|
Response to electrical and magnetic stimulation, singly, will be measured via peak-to-peak amplitude (millivolts) in first dorsal interosseous and abductor pollicis brevis muscles.
|
up to one day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Testosterone
Time Frame: up to one day
|
Serum testosterone will be assessed prior to and after administration of intranasal TRT.
|
up to one day
|
Cardiovagal Function (heart rate variability)
Time Frame: up to one day
|
Changes in beat-by-beat heart rate (beats per minute) signals collected using ECG during a cold face challenge (cardiovagal provocation) to determine cardiovagal reflex function.
Changes in the high frequency (0.15-0.4 Hz) component will be used as an indication of parasympathetic activity to the heart.
|
up to one day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jacob A Goldsmith, PhD, James J. Peters Veterans Affairs Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Trauma, Nervous System
- Spinal Cord Diseases
- Spinal Cord Injuries
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- B5028-M
- 1IK1RX005028-01 (U.S. NIH Grant/Contract: VA Rehabilitation Research & Development)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injury
-
Taipei Veterans General Hospital, TaiwanThe Industrial Technology Research InstituteUnknownSpinal Cord Injuries | Complete Spinal Cord Injury | Incomplete Spinal Cord InjuryTaiwan
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSCI - Spinal Cord Injury | Incomplete Spinal Cord InjuryUnited States
-
Jill M. Wecht, Ed.D.Icahn School of Medicine at Mount SinaiRecruitingBlood Pressure | Spinal Cord Injuries | SCI - Spinal Cord Injury | Blood Pressure Disorders | Traumatic Spinal Cord Injury | Acute Spinal Cord Injury | Neuromodulation | Spinal Cord StimulationUnited States
-
NervGen PharmaRecruitingSpinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord InjuryUnited States
-
MetroHealth Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Case Western...RecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury CervicalUnited States
-
Kevin KilgoreNational Institute of Neurological Disorders and Stroke (NINDS); Case Western... and other collaboratorsRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury Cervical | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C5-C7 Level With Incomplete LesionUnited States
-
The University of Texas Health Science Center,...TerminatedSpinal Cord Injuries | Cervical Spinal Cord Injury | Traumatic Spinal Cord CompressionUnited States
-
StemCells, Inc.TerminatedStudy of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord InjuryCervical Spinal Cord Injury | Spine Injury | Cervical Spine InjuryUnited States, Canada
-
S.Biomedics Co., Ltd.Yonsei University; Linical Co., Ltd.RecruitingSpinal Cord Injury, Acute | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C4 Level With Complete LesionKorea, Republic of
-
Mahidol UniversityRecruitingSpinal Cord Injury | Incomplete Spinal Cord InjuryThailand
Clinical Trials on Ayr Saline Nasal Gel
-
Vanderbilt University Medical CenterCompleted
-
Lori WoodBarrow Brain and SpineRecruitingPituitary TumorUnited States
-
Viiral Nordic ABCompleted
-
Stanford UniversityCompletedNasal ObstructionUnited States
-
Slagelse HospitalZealand University Hospital; Copenhagen University Hospital at Herlev; Holbaek... and other collaboratorsNot yet recruitingAsthma in Children | Bronchiolitis | Respiratory Disease | Acute Respiratory Infection | Viral Infection
-
Sun Yat-sen UniversityZhongshan People's Hospital, Guangdong, China; Fifth Affiliated Hospital of...RecruitingRadiation-Induced MucositisChina
-
AbbVieRecruitingAtrophic Acne ScarsCanada, Germany
-
Acerus Pharmaceuticals CorporationCompletedFemale Sexual DysfunctionUnited States
-
Cardarelli HospitalRecruitingAirway Obstruction | Respiratory Infection | Mucus; PlugItaly
-
Seoul St. Mary's HospitalCompletedAtrophic RhinitisKorea, Republic of